Avalyn Pharma Inc.
AVLNUnited States
2 filed reports · 172 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
2 reports · Mar 2026 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 2 | 553 | Mar 2026 to Jun 2026 |
Financial data
172 concepts · 553 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial170 concepts · 540 facts · Dec 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents6 · Mar 2025 to Jun 2026
- Stockholders equity (US GAAP)6 · Mar 2025 to Jun 2026
- Accounts payable current4 · Dec 2025 to Jun 2026
- Accretion of marketable securities4 · Mar 2025 to Jun 2026
- Accrued liabilities current4 · Dec 2025 to Jun 2026
- Accrued liabilities current and noncurrent4 · Dec 2025 to Jun 2026
- Accrued professional fees current and noncurrent4 · Dec 2025 to Jun 2026
- Accrued research and development costs4 · Dec 2025 to Jun 2026
- Accumulated depreciation depletion and amortization property plant and equipment4 · Dec 2025 to Jun 2026
- Accumulated other comprehensive income loss net of tax4 · Dec 2025 to Jun 2026
- Additional paid in capital common stock4 · Dec 2025 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value4 · Mar 2025 to Jun 2026
- Adjustments to additional paid in capital warrant issued4 · Mar 2025 to Jun 2026
- Allocated share based compensation expense4 · Mar 2025 to Jun 2026
- Amortization and accretion of premiums/discounts on marketable securities4 · Mar 2025 to Jun 2026
- Amortization of debt discount premium4 · Mar 2025 to Jun 2026
- Assets4 · Dec 2025 to Jun 2026
- Assets current4 · Dec 2025 to Jun 2026
- Assets noncurrent4 · Dec 2025 to Jun 2026
- Cash and cash equivalents at carrying value4 · Dec 2025 to Jun 2026
- Common stock par or stated value per share4 · Dec 2025 to Jun 2026
- Common stock shares authorized4 · Dec 2025 to Jun 2026
- Common stock shares issued4 · Dec 2025 to Jun 2026
- Common stock shares outstanding4 · Dec 2025 to Jun 2026
Product1 concepts · 12 facts · Mar 2025 to Jun 2026
- Research and development expense12 · Mar 2025 to Jun 2026
KPI1 concepts · 1 facts · Jun 2026
- Clinical Trial Participants1 · Jun 2026
Segments
12 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service3 members · 12 facts
- Inhaled Pirfenidone One4 · Mar 2025 to Jun 2026
- Inhaled Pirfenidone Three4 · Mar 2025 to Jun 2026
- Inhaled Pirfenidone Two4 · Mar 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.